Contents

Search

drospirenone

Progestational agent. Used in combination oral contraceptive Yasmin. Adverse effects: 1) hyperkalemia [1,2] 2) risk of venous thromboembolism greater for oral contraceptives containing drospirenone vs levonorgestrel (OR=2.4-3.3) [3,4] Mechanism of action: 1) progestational agent 2) antimineralocortocoid activity 3) antiandrogenic activity

Related

ethinyl estradiol/drosperinone (Ocella, Yasmin, Gianvi, Vestura) Yaz

General

progestational agent

Properties

Database Correlations

PUBCHEM correlations

References

  1. Prescriber's Letter 8(6):34 2001
  2. Prescriber's Letter 16(10): 2009 Safety of Drospirenone-Containing Oral Contraceptives Detail-Document#: 251007 (subscription needed) http://www.prescribersletter.com
  3. Jick SS and Hernandez RK Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case- control study using United States claims data BMJ 2011; 342:d2151 PMID: 21511805 http://www.bmj.com/content/342/bmj.d2151 - Parkin L et al Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database BMJ 2011; 342:d2139 PMID: 21511804 http://www.bmj.com/content/342/bmj.d2139 - Dunn N The risk of deep venous thrombosis with oral contraceptives containing drospirenone BMJ 2011; 342:d2519 PMID: 21511807 http://www.bmj.com/content/342/bmj.d2519.extract - FDA Safety Alert: Posted 05/31/2011 Birth Control Pills Containing Drospirenone: Possible Increased Risk of Blood Clots http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm257337.htm
  4. Prescriber's Letter 19(1): 2012 Safety of Drospirenone Contraceptives and the Contraceptive Patch Detail-Document#: 280103 (subscription needed) http://www.prescribersletter.com
  5. FDA MedWatch: 04/10/2012 Birth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm299605.htm

Component-of

Angeliq (drospirenone, estradiol) drospirenone/estradiol drospirenone/estradiol/ethinyl estradiol drospirenone/ethinyl estradiol drospirenone/ethinyl estradiol/metafolin Yaz